January 2013

U.S. stent market: Steps to shedding the metal start in Cincinnati ()
Getting ahead of negative outcomes ()
RVUs ‘inadequate’ in pediatric cath cases ()
Boston Sci to cut staff after sales decline ()
EHR data reveal link between antidepressants, elongated QT ()
FDA clears Kynamro for rare cholesterol condition ()
Societies standardize cardiology definitions, EHR data elements ()
Direct Flow's TAVI system gets EU thumbs up ()
Exclusive: N.J. cardiologist gets $2.4M in whistleblower suit ()
BioFreedom stent approved in Europe ()
Carotid stenting appears safe in high-risk patients ()
FDA green-lights three diabetes drugs ()
Canadian survey places Riata electrical failures at 4.6% ()
Talk to me: Intervention improves docs' communication about meds ()
Left radial access may reduce operator’s radiation exposure ()
ReCor's updated renal denervation system OK’d in Europe ()
Robot gets FDA’s ‘affirmative’ for use in hospitals ()
Drug-eluting balloons may be more effective than DES for restenosis ()
Medtronic obtains CE Mark for vascular stent ()
Reviewing readmissions ()
ISET: EVAR provides survival but not long-term mortality benefit ()
Apixaban gets NICE’s blessing in U.K. ()
Incomplete revascularization leads to adverse outcomes, w/wo total occlusions ()
Large, safety-net hospitals may take brunt of penalties ()
ACC unveils 2013 late-breakers ()
St. Jude sees small drop in sales, earnings for Q4, FY12 ()
Covidien scores CE Mark for EverFlex peripheral stent, delivery system ()
Moody’s: Nonprofit hospital revenue growth likely to shrink ()
Demographics have little impact on HF, MI readmissions ()
Novo Nordisk's diabetes drugs net EU clearance ()
Biomarkers ousting imaging modalities? Not so fast ()
ISET: Combination treatment for DVT appears efficacious ()
IABP in elective high-risk PCI may offer long-term benefit ()
FDA clears thrombectomy system ()
EU approves Gore's updated Excluder AAA Endoprosthesis ()
Complications often precede CPR in surgical patients ()
CoreValve, Sapien/Sapien XT demonstrate equal outcomes at 30 days, 1 year ()
EU clears St. Jude's updated Amplatzer occluder ()
EU body recommends suspending Tredaptive ()
Judge refuses to accept deal in cardiac billing case ()
Pooled blood plasma product OK’d in U.S. ()
Selective D-dimer testing for DVT safe, efficient ()
Let conference season begin ()
Aspirin therapy: Effective but underused ()
Aranesp misses mark in HF trial ()
Erectile dysfunction is sentinel of CV events, mortality ()
ACP offers resources to facilitate high-value care ()
St. Jude’s remote monitoring system gets FDA go-ahead ()
MedPAC recommends 1 percent increase for hospitals ()
FDA gives St. Jude deadline to fix violations ()
CTA & kids: Some under 5 need no anesthesia ()
Harvard, Orca offer cardiac app, iBooks ()
FDA sends warning letter to St. Jude ()
Depression, renal dysfunction increase risk of VAD infection ()
Experts offer guidelines on circulatory support devices ()
Uncompensated care costs hospitals $41.1B in 2011 ()
Statins unlikely to increase diabetes risk in some patients ()
HF: Can observation units reduce readmissions? ()
Polypill proves cost-effective, even in poorer nations ()
FDA panel favors diabetes drug despite CV safety concerns ()
Merck suspends global availability of Tredaptive ()
VTE prophylaxis underutilized, even in high-risk patients ()
Two antihypertensive + NSAID drugs may take toll on kidneys ()
MI guideline adherence spotty with some high-risk patients ()
Hospital, heal thyself ()
Hospital stressors may be catalyst for readmissions ()
Physicians plagued by open malpractice claims ()
MedAxiom: Service lines, savings proliferating ()
Hauser on S-ICDs: Promising, but not for everyone ()
CoreValve demonstrates much higher rate of heart block post-TAVR ()
MR predicts cardiomyopathy recovery ()
Doc resistance to generic statins still evident ()
MedStar Heart Institute aligns with Cleveland Clinic ()
The future of value-based purchasing ()
Physicians often give in to patient demand for brand-name drugs ()
Providers not following guidelines for post-AMI aldosterone antagonist use ()
Bangor medical center, cardiology group merge ()
Cardiovascular Associates, St. Luke’s form partnership ()
Hospital system, cardiologists pay $4.4M in stent case ()
Pathology predicts midterm outcome after endo repair ()
Better outcomes for STEMI patients with transradial PCI approach ()
Renal denervation: Brightest hope since angioplasty? ()
FDA green-lights Xience Xpedition stent ()
SGR: So long and good riddance ()
ICD survival rates similar in clinical trials, practice ()
Hearing set in Mo. overstenting case ()
Is off-label drug marketing simply a matter of free speech? ()
Physician pay cuts averted, temporarily ()